Boston Scientific Receives CE Mark Approval for New Apex(TM) PTCA Dilatation Catheters

    - New Design Offers Greater Flexibility in the Management of Patients
    With Complex Atherosclerosis

    PARIS, Oct. 1 /CNW/ - Boston Scientific Corporation (NYSE:   BSX) announced
today that the Apex(TM) Monorail and Over-The-Wire (OTW) PTCA dilatation
catheters have received CE Mark approval. Both Monorail and OTW catheters are
available in two designs to provide European physicians with further options
for managing patients with complex atherosclerosis (blockage of the arteries).
    Apex is a high-performance balloon catheter that allows physicians to
reach and cross the most challenging atherosclerotic lesions. Designed for use
with drug-eluting stents, Apex has been developed specifically to address
physicians' need for a catheter that can reach not only the furthest blockages
but also cross particularly tight or complex lesions.
    Dr Marie-Claude Morice, head of the Institut Cardiovasculaire Paris Sud,
France, was the first clinician to use catheters from the new Apex product
line. "Apex PTCA dilatation catheters performed well during intervention
procedures," she said. "The catheters are easy to guide through vessels and
can cross lesions efficiently. I welcome innovative designs like Apex, which
should benefit patients by minimising trauma and helping to reduce procedure
    Apex represents a totally new strategy in balloon catheters, giving
today's physicians the technology they need to treat complex lesions. Both
Apex Monorail and OTW catheters are available in two different 1.5 mm designs,
"Apex 1.5 mm Push" and "Apex 1.5 mm Flex". Apex Push offers optimal
pushability for tight lesions, while Apex Flex provides excellent performance
for the most tortuous arteries. The dual Apex 1.5 mm balloon catheter designs
enable physicians to select the appropriate catheter based on the clinical
    "Achieving CE Mark approval is an important step for Apex," said Jeff
Goodman, President of Boston Scientific International. "As a leader in the
field of cardiovascular device technology, Boston Scientific listened and
responded to physicians' requests for improvements to existing catheters. We
are delighted to offer this highly innovative device that addresses
physicians' needs for treating the most difficult and tortuous coronary
    PTCA dilatation catheters are used to open up arteries blocked by
atherosclerosis, which if left untreated can cause heart attacks and strokes
by stopping blood from reaching the heart muscle and brain. Coronary heart
disease by itself is the single most common cause of death in Europe,
accounting for 1.95 million deaths in Europe each year(1).
    Apex is the latest technological development by Boston Scientific to
improve the management of patients with coronary atherosclerosis undergoing
percutaneous coronary intervention (PCI). Boston Scientific enables PCI
optimisation through a broad range of devices, including ultrasound imaging to
assess lesions and balloon catheters and drug-eluting stents to reopen blocked
arteries. This broad portfolio of devices enables physicians to achieve safe
and effective outcomes for their patients.
    Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:

    Cautionary Statement Regarding Forward Looking Statements

    This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended to be
guarantees of future events or performance. These forward-looking statements
include, among other things, product performance, competitive offerings, and
our market position. If our underlying assumptions turn out to be incorrect,
or if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have affected and in
the future (together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our
forward-looking statements.
    Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item IA - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

    Notes For Editors

    Arteries become blocked as a result of a process called atherosclerosis
('hardening of the arteries'), in which the arteries become blocked by a
build-up of fatty deposits (termed 'plaque'). Plaque is made up of fat,
cholesterol, calcium and other substances found in the blood. As it grows, the
build-up of plaque narrows the inside of the artery and, in time, may restrict
blood flow to the heart or the brain leading to heart attack or stroke.
    Blocked arteries can be opened by insertion of a catheter (which is a
thin flexible tube) into the artery (the catheter is actually inserted into
the patient's femoral artery in the groin and guided along the arterial system
to the site of the blockage) and inflation of a tiny balloon at the tip of the
catheter to stretch the artery. When the catheter is removed a tiny rigid
tube, or stent, is left in the artery to keep it open. Rates of stent
placement vary widely but approximately 500 stents are inserted per million
population in Europe(2).
    The CE Mark (Conformité Européenne, or European conformity) is a visible
declaration by a manufacturer that the equipment complies with all applicable
European Union directives on health and safety. This mandatory mark allows
manufacturers and exporters to circulate products freely within European Union
member countries.


    (1) British Heart Foundation Heartstats. (last accessed
    19 April 2007).

    (2) British Heart Foundation Heartstats. (last
    accessed 19 April 2007).

For further information:

For further information: Géraldine Varoqui, Boston Scientific PR Manager
International, Tel: +49-2102-489-461,; Or Tracy Paul, BSC
press office, Tel: +44-20-7413-3101,

Organization Profile

Boston Scientific Corporation

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890